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Abstract: There is ample evidence that synthesis of HIV-1 proviral DNA from the viral 
RNA genome during reverse transcription requires host factors. However, only a few 
cellular proteins have been described in detail that affect reverse transcription and interact 
with reverse transcriptase (RT). HIV-1 integrase is an RT binding protein and a number of 
IN-binding proteins including INI1, components of the Sin3a complex, and Gemin2 affect 
reverse transcription. In addition, recent studies implicate the cellular proteins HuR, 
AKAP149, and DNA topoisomerase I in reverse transcription through an interaction with 
RT. In this review we will consider interactions of reverse transcription complex with viral 
and cellular factors and how they affect the reverse transcription process.  
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1. Overview 
HIV-1 is a member of the lentivirus genus of the family Retroviridae. Like all retroviruses, HIV-1 
is a positive sense (+) single stranded (ss) RNA virus that must integrate its genetic material into the 
host DNA chromosomes to complete its life cycle. This is accomplished in part by the complicated 
process of reverse transcription in which the retroviral enzyme reverse transcriptase (RT) copies the 
(+)ssRNA into double strand DNA. HIV-1 initially enters a target cell as a permeable protein shell 
composed of viral capsid and other proteins and protects the initial steps of reverse transcription from 
cellular detection and degradative processes. A number of different studies now point to interactions 
between the reverse transcription complex, which minimally includes RT and integrase (IN), with 
cellular proteins enabling the production of full length proviral DNA. Here we review the viral 
components of reverse transcription and subsequently critically consider recently described cellular 
factors that help or hinder HIV-1 reverse transcription by directly or indirectly affecting RT.  
2. RT Structure and Function 
RT is an asymmetric heterodimeric enzyme consisting of a 560-amino-acid 66-kDa subunit (p66) 
and a 440-amino-acid 51-kDa subunit (p51)  [1] (Figure 1). The heterodimer contains a single active 
DNA polymerisation site, an RNase H active site and an RNA binding site. 
Figure 1. RT Structure. The p66 subunit is shown in yellow and p51 subunit in purple. A 
vRNA:tRNA structure is juxtaposed on the RT molecule, where the vRNA is green and the 
tRNA is brown. The model was generated and adapted using RasMol and the PBD file ID# 
1R0A  [2]. 
 
 
The p66 subunit of RT can be divided structurally into the polymerase and RNase H domains. The 
polymerase domain can be further differentiated into subdomains that have been described as 
structurally resembling a right hand, forming the fingers, palm, thumb, and connection 
subdomains  [1,3-6]. In the heterodimer, p66 has an “open” conformation, which facilitates binding to 
the incoming RNA template/tRNA complex during reverse transcription  [1,4,7].  Viruses 2009, 1                                       
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While p51 has the same polymerase subdomains as p66, the relative orientations of the individual 
subdomains differ markedly. p51 lacks the cleft domain, as the active polymerase site is buried within 
the structure  [4]. Subsequently p51 forms a “closed” conformation and plays a largely structural role 
to stabilize the RT heterodimer  [8,9], although there is some evidence that the p51 subunit may be 
required for correct binding of the tRNA in the RT binding cleft  [10]. 
 
3. Formation of the HIV-1 Reverse Transcription Initiation Complex in the Mature Virus 
Particle 
 
Interactions between RT and cellular factors are possible during early and late phases of virus 
replication. Two viral proteins, 55 kDa Gag and 160 kDa Gag-Pol, and two unspliced copies of viral 
genomic mRNA form the bulk of nascent virions assembled at the cellular plasma membrane. After 
budding, the virion precursor proteins are processed by the viral protease (PR) into matrix protein 
(MA), capsid protein (CA) and nucleocapsid protein (NC) and p6, and two small spacer proteins from 
Gag; and three viral enzymes: PR, reverse transcriptase (RT) and integrase (IN) from the Pol 
component of Gag-Pol. CA self-assembles into a fullerene cone  [11-13] which contains the genomic 
viral RNA (vRNA) associated with NC, RT, IN, MA and Vpr. Within this CA cone a prototypical 
reverse transcription complex (RTC) is established in the mature virion  [reviewed in 14]. At least two 
cellular factors have been linked to formation of the RTC. A cellular tRNA primer is packaged in 
particles by interaction with Gag with the aminoacyl-tRNA
Lys,3 synthetase (LysRS) which has 
tRNA
Lys,3 bound  [15]. Additional specificity is achieved as only “charged” LysRS molecules (those 
with tRNA
Lys,3 bound) are recruited by additional interaction with the thumb and connection domains 
of Pol (in the Gag-Pol precursor)  [16]. The annealing of tRNA
Lys,3 requires the RNA chaperone 
activity of NC  [17,18]. Additionally, the mechanism by which the tRNA primer is bound to the viral 
RNA involves a complicated mechanism involving interactions between tRNA
Lys,3, LysRS and RT, in 
which contact between Gag, Gag-Pol and LysRS facilitate annealing of non-actylated tRNA
Lys,3 to the 
PBS  [16]. RT binding to LysRS is mediated primarily by the thumb domain, although analysis of 
truncated RT proteins suggested that multiple domains of RT are important. 
RNA interactions between vRNA and tRNA form an RNA architecture which is required for 
initiation of reverse transcription (Figure 2). Although some structural features are controversial, an 
RNA structure determined by chemical and enzymatic probing of synthetic or viral HIV-1 RNA 
annealed to tRNA
Lys,3  [19-23], and recently using high-throughput SHAPE (selective 2’-hydroxyl 
acylation analysed by primer extension) in intact viruses, with ex vivo virus RNA or synthetic 
RNA  [24,25] are similar. This complex is thought to form an RNA “scaffold” bound by reverse 
transcriptase, nucleocapsid and possibly other viral and cellular proteins, which as a whole form the 
reverse transcription initiation complex  [20,21]. A region referred to as the primer activation signal 
(PAS), located approximately 50 nucleotides upstream of the PBS, enhances the usage of tRNA
Lys,3 
and appears to regulate the initiation reaction  [26-28]. However, an interaction between tRNA and 
PAS was not identified by SHAPE analysis suggesting that it may be transient. Generally, mutation of 
these RNA regions often negatively affects the initiation of reverse transcription. Finally, RT has 
contact sites in the vRNA:tRNA complex in addition to the known contact made by p66 in the Viruses 2009, 1                                       
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substrate cleft where the primer:template are clamped  [29]. The p66 fingers subdomain make contacts 
to the vRNA:tRNA complex most likely in U5 just ahead of the tRNA primer.  
Figure 2. Model of the HIV-1 RNA structure from +1 to +540.  Proposed interactions 
between tRNA
Lys,3 and the U5 Stem-loop are indicated. The viral RNA sequence is colored 
black and the tRNA
Lys,3 sequence is in red. TAR: transactivation response element. Poly-A 
Stem loop contains the poly-adenylation signal AAUAAA functions on the 3’ long 
terminal repeat. The ψ indicates the vRNA packaging signal. The PAS on the vRNA and 
the anti-PAS on tRNA
Lys,3 are boxed in green. Adapted from Wilkinson et al. (2008)  [24]. 
 
 
In vitro kinetics studies of reverse transcription indicate that the initiation reaction is significantly 
slower than elongation of the nascent DNA strand by RT. The initiation phase incorporates 1 to 5 
nucleotides to the tRNA primer, followed by a more rapid elongation phase where the polymerization 
rates increase about 3000-fold  [30,31]. Curiously, typical viral genomic RNAs are unextended or have 
a di-nucleotide extension on the primer prior to initiation of reverse transcription  [32]. The initiation 
step of HIV-1 reverse transcription is inhibited by a poorly defined mechanism possibly involving the 
RNA structure described, by low nucleotide concentrations or perhaps by an unknown 
factor  [28,33,34]. 
 
4. The Complexities of Integrase and Reverse Transcriptase 
 
IN is a 288 amino acid, 31 kDa protein making up the C-terminal end of the Gag-Pol protein that 
has three domains consisting of the N-terminal (residues 1-50), catalytic core (residues 51-212), and C-
terminal domain (CTD, residues 213-288). IN is active as a dimer with its primary function being to Viruses 2009, 1                                       
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integrate the viral DNA product  [35]. Its penultimate role is to prepare the viral DNA for insertion into 
the host chromosome. To accomplish this task, IN remains associated with the reverse transcription 
complex, as the double strand viral DNA is made, and transitions into a pre-integration complex (PIC) 
capable of ligating proviral DNA into a chromosome  [36]. IN can directly bind to RT  [37-40] and 
deletion analysis of IN indicates that the CTD, which is a non-specific DNA binding domain  [41-44], 
is necessary and sufficient to bind RT  [39,40]. Conversely, RT reportedly has two IN-binding sites; 
one each in the finger-palm and connection subdomain regions  [39]. The association between IN and 
the RTC appears to be obligatory, as some IN mutants negatively affect proviral DNA 
synthesis  [37,45,46]. Mutations that inhibit reverse transcription are referred to as type II, whereas 
type I mutations affect integration  [47,48]. Recently nuclear magnetic and surface plasmon resonance 
(NMR and SPR, respectively) experiments using a CTD-derived peptide revealed a putative binding 
surface on IN  [49]. One mutation on this surface, K258A, substantially reduced CTD and RT binding. 
An unanswered question about CTD and other type II mutants is whether they act directly on RT, or if 
an interaction between IN and other viral or cellular factors are involved. Evidence that IN and RT 
interaction is required after infection has been inferred from genetic experiments, but rigorous 
correlation between IN and RT interaction and defective reverse transcription requires confirmation. 
Initiation of reverse transcription refers to the addition of the first five deoxynucleotides to the 
tRNA
Lys,3 primer. In vitro experiments using recombinant IN and RT indicate that IN can increase the 
efficiency of initiation [50]. Dobard et al. showed that IN-mediated initiation also requires natural 
tRNA
Lys,3 suggesting that the stability of the RT:primer/template complex is enhanced when IN is 
present. However IN also increases RT elongation dramatically. One possible explanation is that IN 
binding to RT increases the affinity of RT for the template RNA strand, as evident in competition 
assays using molecular traps that can bind RT that disengages the RNA template during DNA 
synthesis. It is unclear why IN is unable to enhance RT elongation when short RNA oligonucleotides 
are used to prime reverse transcription. It is possible that tRNA
Lys,3 is required to form an initial RT-IN 
complex, which is maintained during extended DNA synthesis. Another possibility is that tRNA
Lys,3 
facilitates exposure of an IN binding site on RT. However, this is at odds with the observation that the 
RT-IN interaction does not require an RNA co-factor  [37].  
 
5. IN-Binding Cellular Factors that Affect Reverse Transcription 
 
Yeast-two hybrid systems used to screen libraries of human genes have identified cellular factors 
that interact with integrase  [51-55], which were subsequently confirmed by in vitro protein GST pull-
down and co-immunoprecipitation assays where IN was over expressed in cell culture. These include 
the cellular proteins integrase interactor 1 (INI1, hSNF5)  [53,54], sin3A-associated protein (SAP18), 
histone deactylase 1 (HDAC1)   [52] and survival motor neuron (SMN)-interacting protein 2 
(Gemin2)  [55]. Given that mutation of IN can affect RT activity, it is not surprising that some IN 
binding cellular proteins also affect reverse transcription. Some of these cell proteins and their effects 
are described in the section below. 
 Viruses 2009, 1                                       
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5.1. A role for INI1 in early events during HIV-1 replication? 
 
INI1 is a 385 amino acid, 44 kDa nuclear protein (also called hSNF5, BAF47 and SMARCB1) 
component of the SWI/SNF chromatin remodeling complex that is involved in tumor 
suppression  [56]. INI1 binds to HIV-1 IN as well as proteins from other viruses including E1 from 
human papillomavirus 18 and the EBNA-2 from Epstein-Barr virus regulating virus 
replication  [57,58]. Structurally, INI1 has two imperfect amino acid repeat regions, RPT1 and RPT2, 
and a coiled coil domain that is conserved in other related mammalian and yeast proteins, termed the 
homology region 3 (HR3). INI1 is capable of multimerization and forms high molecular weight 
complexes primarily requiring both RPT motifs (the N-terminal domain also appears to play a 
role)  [59]. Whereas only RPT1 is required to bind IN  [53], a region adjacent to RPT1 in INI1 is 
required to bind DNA along the minor groove. Although primarily a nuclear protein, INI1 has a 
“masked” nuclear export signal (NES) within RPT2 that is critical for its ascribed cellular 
functions  [60].  
INI1 affects HIV-1 replication at several points in the HIV-1 life cycle. In line with its role in the 
SWI/SNF chromatin remodeling complex, INI1 can affect both basal and Tat mediated HIV-1 gene 
expression  [61,62]. INI1 is also required for particle production as exogenously expressed INI1 can 
partially rescue reduced HIV-1 production in cells lacking INI1  [63]. INI1 is specifically packaged in 
HIV-1, but not other retroviruses, and is regulated by a direct interaction between INI1 and the IN 
domain of the HIV-1 Gag-Pol protein  [64]. Several lines of evidence suggest INI1 may be required 
during early steps of HIV-1 replication. Immediately following infection by HIV-1, INI1 in a target 
cell is rapidly and transiently exported from the nucleus by an hCRM1/exportin1 nuclear export 
pathway   [60,65]. INI1 associates with the incoming RTC/PIC in the cytoplasm   [65], and can 
stimulate IN activity in vitro   [53]. Thus, INI1 is a candidate cellular factor regulating RTC/PIC 
activity (Table 1).  
Three recent reports investigating early HIV-1 replication using different experimental approaches 
reached different conclusions regarding INI1 function during early replication. Sorin et al. used two 
rhabdoid tumor-derived cell lines, MON and STA-WTI, which are devoid of functional INI1, to 
produce HIV-1-like particles   [63]. MON and STA-WTI cells transfected with an HIV-1 derived 
lentiviral plasmid made >10-fold less virus than 293T cells. Virus production could be increased by 
exogenously expressing INI1. Interestingly, the INI1 negatively regulated HIV-1 produced from MON 
cells, but not STA-WTI cells, exhibited a sharp defect in reverse transcription and virus infectivity. 
Exogenously expressed INI1 in MON cells did not complement these defects indicating that an 
additional unknown factor was involved in early replication. Curiously, exogenous RT activity in 
MON produced virions was sharply reduced. This is unexpected as RT levels in INI1+ and INI1- 
virions are similar; suggesting that a potent RT inhibitor made in MON cells may be packaged in 
virions. These experiments affirm INI1 as an important factor for virus particle production, but suggest 
that another factor perhaps acting in concert with INI1 is a regulator of reverse transcription (see Sin3a 
complex below) (Figure 3). 
Ariumi et al. investigated INI1 and its role in Tat transactivation of HIV-1 gene expression  [61]. 
Here, INI1 was stably downregulated in CD4+ HeLa-derived P4.2 cells and infected with an HIV-1-
derived lentiviral vector expressing GFP using a CMV promoter (to bypass a need for Tat to monitor Viruses 2009, 1                                       
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gene expression). In this study, no change in virus infectivity was observed. Hence, INI1 had no affect 
on events from fusion to integration, suggesting that INI1 was not essential for RTC or PIC function.  
Maroun et al. down-regulated INI1 in Jurkat or P4.2 cells transiently using siRNA  [66]. In this 
case, HIV-1 replication was enhanced in both cell types indicating that INI1 negatively affected HIV-1 
replication. Infection of INI1 depleted cells resulted in increased levels of 2-LTR circular DNA and 
integrated provirus suggesting that interaction between INI1 and IN somehow inhibited integration. A 
specific IN mutant protein, K71R, blocked the INI1:IN interaction, and HIV-1 with this point mutation 
replicated better leading to the conclusion that INI1:IN complex was detrimental for HIV-1 replication. 
A similar conclusion was previously reported for the homologous recombination repair protein 
RAD52  [67].  
It is clear that INI1 has diverse roles in HIV-1 replication including virus gene expression and virus 
assembly and integration. Sometimes, virus made by cells lacking INI1 display an RT defect, but this 
could be attributed to factors other than INI1. Discrepancies in INI1 function between these 3 studies 
may be due to differences in INI1 expression or cell type specific effects. The suggestion that INI1 has 
innate antiviral activity is intriguing, however further research is required to clarify the role INI1 in 
cells following HIV-1 infection.  
 
5.2. Sin3a-HDAC1complex and early events in HIV-1 replication. 
 
Recently, several Sin3a-HDAC1 complex proteins were found to be specifically packaged in HIV 
virions  [52] (Table1)(Figure 3). In cells, the Sin3a complex is involved in chromatin remodeling 
leading to transcriptional repression  [see 68]. At the heart of this complex is Sin3, a scaffold protein 
able to interact with several proteins simultaneously, which facilitates interaction between numerous 
proteins including transcription factors, histone modifying proteins, and various Sin3a associated 
protein (SAP) including SAP18 and SAP30  [reviewed in 68]. Initially SAP18 was identified by yeast 
two-hybrid analysis, GST pull-down and co-immunoprecipitation assays as an INI1 and IN interacting 
protein  [52]. Subsequently, several different members of the Sin3a-HDAC1 complex were specifically 
detected in HIV-1 virions including Sin3a, Sap18, Sap30, and HDAC1  [52]. Sorin et al. reported that 
they are incorporated in an IN dependent manner which likely involving a protein complex including 
INI1. The significance of HDAC1 activity in virions was tested by overexpression of a dominant 
negative HDAC1 mutant (H141A), by reducing HDAC1 expression using siRNA, or using chemical 
inhibitors of HDAC activity  [52]. These approaches resulted in reduced (~3-fold) HIV-1 infectivity 
suggesting that HDAC activity was important for early steps in HIV-1 infection. This was not 
attributed to a defect in virus maturation or ability of HIV-1 to fuse to a target cell. Curiously, a 
substantial defect in synthesis of reverse transcription products was observed, 10 to 100 fold, which 
indicated that a step between uncoating and reverse transcription was affected by HDAC1. Overall, the 
decreased infectivity was somewhat modest compared to the observed defect in viral cDNA synthesis. 
Nevertheless, components of the Sin3a complex, which includes INI1, plays a role in early steps of 
HIV-1 replication.  
Exploration of the role of Sin3a, SAP18, Sap30 and HDAC1 should provide significant insight to 
virus replication strategies. Sin3a, as previously mentioned, is a scaffold protein, but no specific 
functions are known for Sap18 and Sap30 other than they are associated within stable protein Viruses 2009, 1                                       
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complexes often involving transcription factors. It is possible that they perform a similar function by 
stabilizing the reverse transcription or pre-integration complexes. While HDAC1 activity is important 
for HIV-1 infectivity, the viral substrate for HDAC1 is unknown. The only HIV-1 proteins regulated 
by HDAC and histone acetyltransferase activity (HAT) are Tat and IN  [69-74]. Acetylation of K51 in 
Tat positively affects HIV-1 gene expression  [69,71,75,76], and this post-translational modification 
can be opposed by human sirtuin 1 (SIRT1) [77], a nicotinamide adenine dinucleotide-dependent class 
III protein deacetylase. Integrase can be acetylated by p300 on three lysine residues, K264, K266, and 
K273 in the C-terminal domain. Interestingly, mutating IN residues K264 or K266 resulted in 
defective reverse transcription   [47] opening up the possibility of regulation of IN function by a 
reversible post-translational modification by p300 and a deactylase activity.  
 
5.3. Survival motor neuron complex member Gemin2; an essential reverse transcription co-factor. 
 
Gemin2 (also called SMN-interacting protein 1, SIP1) is 280 amino acid, 30 kDa protein and a 
component of the survival motor neuron (SMN) complex composed of SMN, Gemins2-8 and Unrip 
proteins  [reviewed in 78]. The primary role of the SMN complex in the cell is in the biogenesis of 
small nuclear ribonucleoproteins, which are assembled in the cell cytoplasm and accumulate in 
specific structures in the nucleus called gems (Gemini or coiled bodies)  [79]. Gemin2 was originally 
identified as an IN binding protein in a yeast two-hybrid protein interaction assay  [55], where Gemin2 
amino acids 137 to 238 mediate binding to the C-terminal domain (amino acids 213-288) of HIV-1 IN 
(Table 1)(Figure 3). Hamamoto et al. showed that downregulation of Gemin2 expression by siRNA in 
primary monocyte derived macrophage cells significantly reduced HIV-1 replication that was 
attributed to reduced efficiency of reverse transcription and integration  [55]. Thus, Gemin2 is required 
for an early event post-infection that affects early reverse transcription product (negative strand strong 
stop) less than later products or integrated DNA, suggesting that Gemin2 associates with either the 
reverse transcription or pre-integration complexes   [55]. Alternatively, Gemin2 could recruit other 
cellular factors required for reverse transcription. For example DHX9 (RNA helicase A) is putative 
cellular factor regulating reverse transcription  [80] that can associate with the SMN complex [81] . It 
is possible that other SMN complex proteins are also important. The difficulty in resolving this issue is 
that the steady state level of Gemin2 and SMN appear to be co-dependent. That is, the downregulation 
of either protein by siRNAi leads to reduced levels of the other  [55]. Thus determining a role for SMN 
in early replication that is distinct from Gemin2 is problematic. Curiously, only one of four recent 
genome wide screens using RNAi methods   [82-85] identified Gemin2   [82] as a HIV-1 human 
dependency factor, and SMN was not identified in any screen. The precise mechanism of how Gemin2 
affects early replication remains to be determined.  
 Viruses 2009, 1                                       
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Figure 3. Schematic of RTC interacting cellular factors. Known direct (—) and   
indirect (---) associations between RTC (blue) and host factors that affect reverse 
transcription. Cellular factors are incorporated into virion particles (green), not 
incorporated (yellow) or conditionally incorporated (red). 
 
 
6. Do Cellular Factors Directly Affect Reverse Transcription via RT Association? 
 
The importance of host cell factors for HIV replication was recently highlighted by siRNA library 
genomic screens  [82-85]. Each screen identified approximately 200-300 genes which affected HIV 
replication, with minimal overlap of genes between the individual screens. Interestingly, three of the 
studies identified host factors important for reverse transcription  [83-85]. As there are other recent 
analyses of these genomic screens  [86-88], in the section below we will instead focus on specific 
examples in the literature in which there is evidence of RT associations that affect reverse 
transcription. 
 
6.1. Human antigen R (HuR): an effector of multiple steps of HIV-1 replication 
 
HuR (also referred to as ELAVL1, HuA and MelG), is a ubiquitously expressed 326 amino acid, 36 
kDa nuclear protein that possesses nucleocytoplasmic shuttling capabilities  [89]. Like all members of 
the ELAV-like protein family, HuR exhibits high specificity and affinity for AU-rich elements (AREs) 
and contains 3 RNA binding domains. A direct correlation between HuR expression and mRNA decay 
has been demonstrated, thus implicating a role in the ARE-mediated mRNA degradation   
pathway  [90-93]. A protective role for HuR in this pathway was suggested by the observation that Viruses 2009, 1                                       
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overexpression of HuR in mouse cell lines significantly increased the stability of both type I and type 
II ARE-containing mRNAs   [89,94]. Interestingly, studies have suggested that nucleocytoplasmic 
shuttling of HuR may regulate its function and whilst the precise mechanism behind the nuclear export 
of the protein remains unclear, it is most likely that HuR binds ARE-containing mRNAs in the 
nucleus, accompanies them to the cytoplasm, and then returns to the nucleus upon release.  
Recently, altering HuR levels in cells has been shown to affect early HIV-1 replication   [95]   
(Table 1)(Figure 3). Both depletion and overexpression of HuR verified the requirement of this protein 
for optimal reverse transcription. While the mechanism behind this activity remains unclear, it appears 
to be due to HuR an interaction with the RNase H domain of RT [95], as opposed to the previously 
discussed protein-RNA binding that regulates the role of HuR in mRNA stability. It is also possible 
that such activities are dependent on the presence of cellular factors that bind and regulate HuR. For 
example, HuR is incorporated in cellular stress granules that are common sites of regulation of mRNA 
stability and translation  [96-98]. Interestingly human APOBEC3G (hA3G), known to have negative 
effects on reverse transcription  [99-102], also localizes to stress granules  [103]. Furthermore, hA3G 
was found to associate with a number of ribonucleoproteins present in stress granules   [103], a 
significant proportion of which are known mRNA-interacting proteins including DHX9   [80,104], 
HNRNPU  [105], PABPC1  [106], YB-1  [83,107] and SNRPA  [83] that have previously been shown 
to affect various steps of HIV-1 replication including reverse transcription. Most significantly, a direct 
interaction between hA3G and HuR was revealed  [103]. Hence, a HuR/hA3G protein complex could 
regulate the RTC as it progresses through the cytoplasm. Alternatively, HuR or DHX9 could oppose 
the negative effects of hA3G on HIV-1 reverse transcription. Further analysis of will be required to 
clarify a role for HuR:RT interaction.  
 
6.2. A kinase anchor protein 1 (AKAP1): anchoring HIV-1 reverse transcription? 
 
AKAP1, more commonly referred to as AKAP149 or PRKA1, is a member of the AKAP family of 
proteins which bind the regulatory subunits of cAMP-dependent protein kinase A (PKA) and anchors 
them to various membranes throughout the cell  [108,109]. AKAP149 binds both RI and RII subunits 
of PKA, attaching them to the outer mitochondrial membrane  [110], where it also interacts with c-myc 
binding protein (MYCBP, also called AMY-1), phosphodiesterase 4 (PDE4) and potentially caveolin 1 
(CAV1)   [111-113]. In addition to mitochondria, AKAP149 also exhibits localization to the 
endoplasmic reticulum and nuclear envelope where it assists the maintenance of nuclear integrity 
through interactions with B-type lamin (LMNB) and protein phosphatase 1 (PP1)  [114-117]. A feature 
of the AKAP149 protein is the presence of a KH-Tudor domain  [108] that facilitates both RNA-
binding and self-association properties  [118,119] . 
Recent research has demonstrated a direct interaction between AKAP149 and HIV-1 RT   [95] 
(Table 1). Like HuR, AKAP149 binds to the RNase H region of RT [124]. While siRNA knockdown 
experiments indicate that this interaction is essential for optimal reverse transcription, a direct role for 
AKAP149 in reverse transcription requires confirmation. AKAP149 is not incorporated into virions 
and localizes to the endoplasmic reticulum, nuclear envelope and mitochondria  [114,117,120]. While 
point mutation of the RNase H domain sharply downregulate AKAP149:RT interaction and reverse 
transcription, a clear connection has not been established. How AKAP149 is able to interact with RT Viruses 2009, 1                                       
 
 
883
prior to its function in reverse transcription is currently unknown, however AKAP149 does interact 
with cellular factors that could affect reverse transcription. For example, AKAP149 anchors PKA and 
PDE4 to mitochondria, both of which have been implicated in the regulation of HIV-1 
replication  [121,122]. PKA is incorporated into HIV-1 virions and can phosphorylate HIV-1 CA, an 
activity that may be important for viral infectivity  [123]. Also, PKA and PDE4 themselves are key 
players in the cAMP signaling pathways  [124], which can stimulate HIV-1 from latently infected 
cells   [122,125] and in turn, can be activated by HIV-1 in normal lymphocytes   [126]. Hence 
AKAP149 could affect reverse transcription indirectly, perhaps through a protein kinase dependent 
signaling pathway.  
 
6.3. DNA topoisomerase 1 (TOP1) and increased RT efficiency 
 
TOP1 is a 91 kDa sumoylated enzyme that regulates the topologic state of DNA during the process 
of transcription. TOP1 activity is required for optimal replication of many different DNA and RNA 
viruses including equine infectious anaemia virus (EIAV), Rous sarcoma virus (RSV), herpes simplex 
virus 1 (HSV1), adenovirus type 5 (Ad5), simian virus 40 (SV40) and HIV-1  [127-132].  
Table 1. Summary of host factors that affect reverse transcription. 
Host  
factor 
Found 
in 
virus 
particle 
Virus  
binding 
partner 
RT/IN 
binding site 
Affect on 
reverse 
transcription 
Other binding  
partners with 
respect to RT 
Reference 
INI1  Yes  IN  NH2-terminal; 
zinc-finger 
region 
Unclear, recruits 
Sin3a complex 
proteins to the 
virion 
HIV-1 TAT;  
SAP18 
[52,53,61,63,66] 
SAP18  Yes IN  n/d  unknown,   
recruits Sin3a 
complex proteins 
to the virion 
INI1 [52] 
HDAC1  Yes  nil  n/a  required for 
early 
reverse  
transcription 
INI1  [52] 
Gemin2  No IN  C-terminal 
region; 
amino acids  
213-288 
required for early 
reverse  
transcription 
SMN1; 
DHX9 (but 
indirectly 
through the 
SMN complex) 
[55,80] 
HuR  n/d  RT  RNAse H 
domain 
required for early 
reverse 
transcription 
APOBEC3G  [95,103] 
 
AKAP149  No RT RNAse  H 
domain 
required for early 
reverse 
transcription 
PKA, PDE4,   [120,121,126] 
TOP1  Yes  NC  n/a  stimulates RT 
activity 
n/a  [132,134,135] 
APOBEC3G  Yes, if  
Vif is  
absent 
NC; viral 
RNA/DNA 
n/a inhibits  early 
reverse 
transcription 
& inhibits 
elongation of viral 
cDNA 
HuR [99-102]   
DHX9 
(RHA, RNA  
helicase A) 
Yes  Gag, viral RNA  n/a  required for early 
reverse 
transcription 
SMN complex, 
APOBEC3G 
[80,103] 
n/d = not determined 
n/a = not applicable Viruses 2009, 1                                       
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TOP1 has been shown to enhance HIV-1 cDNA synthesis  [133,134], thus implicating a role for this 
enzyme in reverse transcription (Table 1)(Figure 3). Interestingly, TOP1 has been shown to directly 
interact with HIV-1 NC  [134], which itself is essential for the initiation of reverse transcription  [135]. 
Additionally,  in vitro reverse transcription assays have demonstrated that TOP1 can significantly 
enhance the activity of HIV-1 RT  [134] and this can be impeded by the addition of the TOP1 inhibitor 
camptothecin  [134]. While the exact mechanism behind this activity has yet to be elucidated, TOP1 
may dissociate RT from structured RNA   [136] in an ATP-dependent manner   [137,138]. 
Alternatively, an enzymatic difference between cellular and virus-derived TOP1 has been suggested 
although this notion is controversial  [131,134,137].  
Also interesting is the ability of TOP1 to regulate virus tropism. HIV-1 virions derived from 
African green monkey cells are known to be less infectious than those derived from human 
cells  [139]. Studies by Shoya et al  [133] demonstrated that expression of human TOP1 in African 
green monkey cells increases the infectivity of progeny virions to 50-60% of that observed from 
human cells which was attributed to enhanced reverse transcription. Further research is required to 
determine the mechanism by which TOP1 enhances reverse transcription process. This could reveal 
whether this TOP1 activity is a possible candidate for the development of antiretroviral therapy. 
7. Conclusions  
Given that HIV-1 encodes only 9 genes and 15 proteins, it is not surprising that HIV-1 uses many 
hundreds of cellular factors during the virus replication cycle. Recent reports of human genome 
screens using RNAi methods and proteomic analysis have identified a plethora of human dependency 
factors, but few have been studied in detail. The question of which cellular components are required 
for productive reverse transcription will undoubtedly have a complicated answer. The RT:IN complex 
recruits cellular proteins that are required to complete reverse transcription, and its highly likely that 
other viral factors, such as NC, Vpr, MA, and Tat do the same. The research highlighted here begins to 
reveal how some factors regulate RT activity, but whether these factors are RTC components, or if 
they direct the RTC is unknown. The proteins discussed here provide a starting point towards 
understanding complex host-pathogen interactions that makes productive reverse transcription in cells 
possible. The investigations of cellular factors give hope that unraveling the critical interactions will 
ultimately be the key to novel treatments for HIV-1 infection. 
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